Comparison of thromboembolic risk scores for evaluating in-hospital events of COVID-19 patients.

Aim: To compare the effectiveness of thromboembolic risk scores in determining in-hospital events of COVID-19 patients. Methods: This retrospective study included a total of 410 consecutive COVID-19 patients. Scores including CHA 2 DS 2 -VASc-HS (congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, vascular disease, sex, hyperlipidemia, smoking); modified R 2 CHA 2 DS 2 -VASc (CHA 2 DS 2 -VASc plus renal function), m-ATRIA (modified Anticoagulation and Risk Factors in Atrial Fibrillation score), ATRIA-HSV (ATRIA plus hyperlipidemia, smoking and vascular disease) and modified ATRIA-HSV were calculated. Participants were divided by in-hospital mortality status into two groups: alive and deceased. Results: Ninety-two (22.4%) patients died. Patients in the deceased group were older, predominantly male and had comorbid conditions. CHA 2 DS 2 -VASc-HS (adjusted odds ratio [aOR]: 1.31; p = 0.011), m-R 2 CHA 2 DS 2 -VASc (aOR: 1.33; p = 0.007), m-ATRIA (aOR: 1.18; p = 0.026), ATRIA-HSV (aOR: 1.18; p = 0.013) and m-ATRIA-HSV (aOR: 1.24; p = 0.001) scores were all associated with in-hospital mortality. m-R 2 CHA 2 DS 2 -VASc and modified ATRIA-HSV had the best discriminatory performance. Conclusion: We showed that m-R 2 CHA 2 DS 2 -VASc and m-ATRIA-HSV scores were better than the rest in predicting mortality among COVID-19 patients.